The field of the invention generally relates to embolic devices for filling spaces in the vascular system, including cerebral aneurysms or left atrial appendages. In some case, the embolic devices may be used to embolize native vessels.
An embolic device may be used as a stand-alone device to occlude and aneurysm, or may be used with an adjunctive device or material.
In one embodiment of the present disclosure, an apparatus for treating an aneurysm in a blood vessel includes an occlusion element configured to be releasably coupled to an elongate delivery shaft and having a distal end, a proximal end and a longitudinal axis extending between the distal end and the proximal end, the occlusion element including an inverted mesh tube having an outer layer and an inner layer, the outer layer transitioning to the inner layer at an inversion fold, the inversion fold defining a first inner diameter, the inner layer defining a maximum inner diameter, and the outer layer defining a maximum outer diameter, the maximum inner diameter and the maximum outer diameter both residing within a first plane transverse to the longitudinal axis, the first inner diameter residing within a second plane transverse to the longitudinal axis.
In another embodiment of the present disclosure, an apparatus for treating an aneurysm in a blood vessel includes an occlusion element configured to be releasably coupled to an elongate delivery shaft and having a distal end, a proximal end, and a longitudinal axis extending between the distal end and the proximal end, a occlusion element configured to be delivered in a collapsed configuration through an inner lumen of a delivery catheter, the inner lumen having a proximal end and a distal end, the occlusion element further configured to expand to an expanded configuration when advanced out of the distal end of the inner lumen of the delivery catheter and into the aneurysm, the occlusion element including an inverted mesh tube having an outer layer and an inner layer, the outer layer transitioning to the inner layer at an inversion fold located at or adjacent the distal end of the occlusion element, the inversion fold defining an inner diameter, the occlusion element further including a maximum outer diameter, wherein the inner diameter is between about 35% to about 85% of the maximum outer diameter, and wherein an outer diameter of the occlusion element increases along the longitudinal axis to the maximum outer diameter.
Aneurysms are abnormal bulging or weakening of a blood vessel, often an artery, and can have many complications. A bulging of the blood vessel can disrupt or put pressure on surrounding tissues. Cerebral aneurysms can result in a variety of side effects, such as impaired vision, impaired speech, impaired balance, etc. Further, the aneurysm creates a volume that is not along the main flow path of the blood through the blood vessel. It therefore can serve as a location for blood to become stagnant and, due to swirling eddy currents, can contribute to the formation of a thromboembolism. If an aneurysm ruptures, it can cause severe internal bleeding, which in cerebral arteries can often become fatal.
Aneurysms can be treated externally with open surgery. Such procedures typically involve closing off the entrance or “neck” of the aneurysm with a device such as vascular clip, clamp or a ligature. However, such open surgical procedures can be highly invasive and may lead to trauma to the adjacent tissue and other side effects.
Aneurysms can also be treated through endovascular procedures. In one procedure, detachable lengths of wires (e.g., coils) are inserted into the interior volume of the aneurysm using a catheter. The coils are intended to fill the volume of the aneurysm to decrease the flow of blood into the aneurysm, inducing stagnation of flow and stimulate clotting within the aneurysm. In settings of large cerebral aneurysms, filling of the aneurysm with multiple coils can lead to mass effect that may induce brain swelling and be an independent cause for new symptoms. In another procedure, for aneurysms with a relatively large neck, the adjunctive use of stents assists with the retention of the coils within the aneurysm. This approach may have a contraindication to being used when treating ruptured aneurysm, due to the need for additional anti-thrombotic medications. In another procedure, the coils are held in the volume of the aneurysm with a temporary balloon that is inflated in the blood vessel. The balloon is deflated and removed once the mass of coils is secured. In still another procedure, a stent device is placed in the artery to promote flow of blood past the aneurysm. This leads to stagnation of the blood within the aneurysm and thrombosis inside the aneurysm volume. However, a side branch of a main artery in which the stent device is placed may become trapped or “jailed,” which can impede access to the side branch. In other instances, the side branch can become clotted off, possibly causing a stroke. Additionally, such a procedure generally requires the use additional anti-thrombotic medications, which limits the use of such devices in the setting of treatment of ruptured aneurysms. The stent device is often formed with a relatively tight weave. While the tight weave increases the effectiveness of the stent device in diverting the blood flow, it also impedes or prevents access to the volume of the aneurysm or the jailed artery. In the event that the aneurysm fails to clot, the obstruction of the aneurysm by the stent device prevents the possibility of placing embolic devices inside the aneurysm. Additional procedures such as the placement of additional stents or open surgery may then be required to treat the residual.
Procedures that involve packing the volume of the aneurysm can suffer from several common shortcomings. First, it can take many coils of wire to fill the volume of the aneurysm, which is time consuming and increases the time it takes to complete the procedure. Further, the coils may be compacted over time to occupy a smaller percentage of the total volume of the aneurysm. A great enough compaction of the coils can be considered a recurrence of the aneurysm and may require further treatment.
The distal orifice 446 can be sized to control the overall width of the substantially flattened portion 440. The smaller the distal orifice 446, the thicker the width (on each side of the orifice 446) in the substantially flattened portion 440. The thicker the width of this portion, the more radial force (aneurysm gripping force) can be placed on the aneurysm wall by the maximum diameter portion 436. In some embodiments, the inner diameter of the orifice 446 is between about 35% to about 85% the diameter of the maximum outer diameter portion 463. In some embodiments, the inner diameter of the orifice 446 is between about 45% to about 75% the diameter of the maximum outer diameter portion 463. In some embodiments, the inner diameter of the orifice 446 is between about 50% to about 70% the diameter of the maximum outer diameter portion 463. In some embodiments, the inner diameter of the orifice 446 is between about 55% to about 65% the diameter of the maximum outer diameter portion 463. In some embodiments, the orifice 446 is on the same plane as the maximum outer diameter portion 463. In other embodiments, the orifice 446 is on a plane that is distal to a plane generally carrying the maximum outer diameter portion 463. In other embodiments, the orifice 446 is on a plane that is proximal to a plane generally carrying the maximum outer diameter portion 463.
The occlusion device 450 is coupled to a pusher wire 481 and is delivered through a microcatheter 485 that is placed through the main artery 495. After being deployed in the desired position, the occlusion device 450 is released from the pusher wire 481 by detachment at a detachable joint 489. A detachable joint 489 may comprise one of a number of detachment systems, including but not limited to pressurized detachment, electrolytic detachment mechanisms, hydraulic detachment mechanisms, mechanical or interlocking detachment mechanisms, chemical detachment mechanisms, heat-activated detachment systems, or frictional detachment systems. During delivery, the pusher wire 481 is held on its proximal end (not shown) by a user and pushed in a forward longitudinal direction, in order to advance the occlusion device 450 to the distal end 493 of the delivery catheter (microcatheter) 485.
The flush or adjacent relation of the proximal end 1052 of the internal tube 1046 to a proximal end 1054 of the mesh cover 1042 assures that there is no detachment remnant extending substantially proximal to the proximal end 1054 of the mesh cover 1042 (and into the parent artery). Thus, any potentially related thromboembolic events may be avoided, in cases wherein such a remnant would be a risk. In some embodiments, the minimum outer diameter of the mesh cover 1042 is between about 70% and about 90% of the maximum outer diameter of the mesh cover 1042.
The bowl-shaped element 602 is configured to cover a neck portion of an aneurysm. The maximum diameter portion 614 can be configured to engage a wall portion of the aneurysm to maintain the occlusion device 600 in place. For example, the diameter of the maximum diameter portion 614 can be oversized in relation to the target aneurysm diameter, e.g., 10% greater, 20% greater, etc. As shown in
While the foregoing is directed to embodiments of the present disclosure, other and further embodiments may be devised without departing from the basic scope thereof. The filament diameter of the filaments comprising any of the mesh material (e.g., mesh tube including inverted mesh tubes) described herein may be between about 0.0004 inch and about 0.003 inch, or between about 0.0005 inch and about 0.002 inch, or between about 0.0006 inch and about 0.002 inch, or between about 0.0006 inch and about 0.0015 inch. The drawn filled tubes (DFT) may comprise between 0% and 100% of the total strands/filaments in any of the braided/mesh tubes. In some embodiments, the drawn filled tubes (DFT) comprise about 50% to about 100% of the total filaments of the cover and about 50% to about 100% of the total filaments of each of the doubled-over or looped tubular mesh. The radiopaque core of each of at least some of the drawn filled tubes has a cross-sectional area that is between about 10% and about 70% of the total cross-sectional area of the each of at least some of the drawn filled tubes, or between about 51% and about 70% of the total cross-sectional area of the each of at least some of the drawn filled tubes. In some embodiments, NiTi #1-DFT® wire produced by Fort Wayne Metals Research Products Corp. (Fort Wayne, Ind. USA) may be utilized. The filaments may be braided with patterns having filament crossings that are in any one or more of the following ratios of filaments: 1×1, 1×2, 2×1, 2×2, 2×3, 3×2, 3×3, etc. (e.g., warp and weft). Any low, moderate, or high pick counts may be used, for example, between about 15 picks per inch and about 300 picks per inch, or between about 20 picks per inch and about 160 picks per inch. Any of the filaments or any of the portion of the occlusion devices may be coated with compounds that enhance endothelialization, thus improving the healing process when implanted within the aneurysm, and optimizing occlusion. The pusher and occlusion device configurations presented herein may also be used for in other types of implantable devices, such as stents, flow diversion devices, filters, and occlusion devices for structural heart defects.
Additional materials may be carried on a proximal portion of the occlusion device, and configured to face opposite the aneurysm neck. In some embodiments, the material on the occlusion device may comprise a biological layer, configured to encourage growth. In some embodiments, the biological layer may comprise antibodies, in order to accelerate the formation of an endothelial layer, for example, by attracting endothelial progenitor cells (EPCs). In some embodiments, the biological layer may comprise a natural membrane or structure, such as a membrane, such as a membrane from an ear, or a cornea, or an ultra-thin piece of ligament, or even a piece of blood vessel wall. In some embodiments, the material on the occlusion device may comprise a polymer layer configured to act as a simulated arterial wall. In some embodiments, the polymer layer may comprise polytetrafluoroethylene, such as expanded polytetrafluoroethylene (ePTFE), such as that used in grafts.
In some embodiments, braided elements may be subsequently etched (chemical etch, photochemical etch) to decrease the overall wire diameter and decrease the stiffness.
The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “approximately”, “about”, and “substantially” as used herein include the recited numbers (e.g., about 10%=10%), and also represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.
For purposes of the present disclosure and appended claims, the conjunction “or” is to be construed inclusively (e.g., “an apple or an orange” would be interpreted as “an apple, or an orange, or both”; e.g., “an apple, an orange, or an avocado” would be interpreted as “an apple, or an orange, or an avocado, or any two, or all three”), unless: (i) it is explicitly stated otherwise, e.g., by use of “either . . . or,” “only one of,” or similar language; or (ii) two or more of the listed alternatives are mutually exclusive within the particular context, in which case “or” would encompass only those combinations involving non-mutually-exclusive alternatives. For purposes of the present disclosure and appended claims, the words “comprising,” “including,” “having,” and variants thereof, wherever they appear, shall be construed as open-ended terminology, with the same meaning as if the phrase “at least” were appended after each instance thereof.
This application claims the benefit of priority to U.S. Provisional Patent Application No. 62/852,988, filed on May 25, 2019, U.S. Provisional Patent Application No. 62/914,442, filed on Oct. 12, 2019, U.S. Provisional Patent Application No. 62/975,741, filed on Feb. 12, 2020, and U.S. Provisional Patent Application No. 62/975,744, filed on Feb. 12, 2020, all of which are herein incorporated by reference in their entirety for all purposes. Priority is claimed pursuant to 35 U.S.C. § 119.
Number | Name | Date | Kind |
---|---|---|---|
5250071 | Palermo | Oct 1993 | A |
5282806 | Haber et al. | Feb 1994 | A |
5304195 | Twyford, Jr. et al. | Apr 1994 | A |
5556390 | Hicks | Sep 1996 | A |
5795331 | Cragg et al. | Aug 1998 | A |
5935148 | Villar et al. | Aug 1999 | A |
6086577 | Ken et al. | Jul 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6391037 | Greenhalgh | May 2002 | B1 |
6454780 | Wallace | Sep 2002 | B1 |
6506204 | Mazzochi | Jan 2003 | B2 |
6510811 | Gore et al. | Jan 2003 | B1 |
6544163 | Wallace et al. | Apr 2003 | B2 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6936055 | Ken et al. | Aug 2005 | B1 |
6994689 | Zadno-Azizi et al. | Feb 2006 | B1 |
7128736 | Abrams et al. | Oct 2006 | B1 |
7195636 | Avellanet et al. | Mar 2007 | B2 |
7229461 | Chin et al. | Jun 2007 | B2 |
7410482 | Murphy et al. | Aug 2008 | B2 |
7569066 | Gerberding et al. | Aug 2009 | B2 |
7749242 | Tran et al. | Jul 2010 | B2 |
8142456 | Rosqueta et al. | Mar 2012 | B2 |
8333796 | Tompkins et al. | Dec 2012 | B2 |
8388650 | Gerberding et al. | Mar 2013 | B2 |
8398670 | Amplatz et al. | Mar 2013 | B2 |
8551132 | Eskridge et al. | Oct 2013 | B2 |
8597320 | Sepetka et al. | Dec 2013 | B2 |
8728117 | Janardhan et al. | May 2014 | B1 |
8777979 | Shrivastava et al. | Jul 2014 | B2 |
8820207 | Marchand et al. | Sep 2014 | B2 |
8826791 | Thompson et al. | Sep 2014 | B2 |
8864790 | Strauss et al. | Oct 2014 | B2 |
8864791 | Bloom et al. | Oct 2014 | B2 |
8940015 | Kariniemi | Jan 2015 | B2 |
8998947 | Aboytes et al. | Apr 2015 | B2 |
9107670 | Hennes et al. | Aug 2015 | B2 |
9198668 | Theobald et al. | Dec 2015 | B2 |
9259337 | Cox et al. | Feb 2016 | B2 |
9314326 | Wallace et al. | Apr 2016 | B2 |
9585670 | Hines | Mar 2017 | B2 |
9597087 | Marchand et al. | Mar 2017 | B2 |
9636117 | Bachman et al. | May 2017 | B2 |
9669188 | Echarri et al. | Jun 2017 | B2 |
9855052 | Aboytes et al. | Jan 2018 | B2 |
9918720 | Marchand et al. | Mar 2018 | B2 |
9980733 | Badruddin et al. | May 2018 | B2 |
10111670 | Lorenzo et al. | Oct 2018 | B2 |
10136896 | Hewitt et al. | Nov 2018 | B2 |
10149676 | Mirigian et al. | Dec 2018 | B2 |
10478195 | Aboytes et al. | Nov 2019 | B2 |
10751065 | Soto Del Valle et al. | Aug 2020 | B2 |
20020169473 | Sepetka | Nov 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20030171770 | Kusleika et al. | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030195553 | Wallace et al. | Oct 2003 | A1 |
20040034386 | Fulton et al. | Feb 2004 | A1 |
20040044391 | Porter | Mar 2004 | A1 |
20040172056 | Guterman et al. | Sep 2004 | A1 |
20040199201 | Kellett et al. | Oct 2004 | A1 |
20050033409 | Burke et al. | Feb 2005 | A1 |
20050107823 | Leone et al. | May 2005 | A1 |
20050171478 | Selmon et al. | Aug 2005 | A1 |
20050277978 | Greenhalgh | Dec 2005 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060106417 | Tessmer et al. | May 2006 | A1 |
20060155323 | Porter et al. | Jul 2006 | A1 |
20070173928 | Morsi | Jul 2007 | A1 |
20070208376 | Meng | Sep 2007 | A1 |
20070225794 | Thramann et al. | Sep 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20080045997 | Balgobin et al. | Feb 2008 | A1 |
20080097495 | Feller, III et al. | Apr 2008 | A1 |
20080147100 | Wallace | Jun 2008 | A1 |
20080281350 | Sepetka | Nov 2008 | A1 |
20080319533 | Lehe | Dec 2008 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090082803 | Adams | Mar 2009 | A1 |
20090099647 | Glimsdale | Apr 2009 | A1 |
20090177261 | Teoh et al. | Jul 2009 | A1 |
20090264978 | Dieck et al. | Oct 2009 | A1 |
20090287291 | Becking | Nov 2009 | A1 |
20090318941 | Sepetka et al. | Dec 2009 | A1 |
20100179583 | Carpenter et al. | Jul 2010 | A1 |
20110046719 | Frid | Feb 2011 | A1 |
20110202085 | Loganathan | Aug 2011 | A1 |
20120065667 | Javois et al. | Mar 2012 | A1 |
20120071911 | Sadasivan et al. | Mar 2012 | A1 |
20120143317 | Cam et al. | Jun 2012 | A1 |
20120259244 | Roberts et al. | Oct 2012 | A1 |
20120283768 | Cox | Nov 2012 | A1 |
20120303052 | Connor | Nov 2012 | A1 |
20120310270 | Murphy | Dec 2012 | A1 |
20120330347 | Becking | Dec 2012 | A1 |
20130066357 | Abotes et al. | Mar 2013 | A1 |
20130073026 | Russo | Mar 2013 | A1 |
20130190800 | Murphy et al. | Jul 2013 | A1 |
20130211495 | Halden | Aug 2013 | A1 |
20140005714 | Quick | Jan 2014 | A1 |
20140012303 | Heipl | Jan 2014 | A1 |
20140052233 | Cox | Feb 2014 | A1 |
20140172001 | Becking | Jun 2014 | A1 |
20140257360 | Keillor | Sep 2014 | A1 |
20140277013 | Sepetka et al. | Sep 2014 | A1 |
20140343602 | Cox et al. | Nov 2014 | A1 |
20150005811 | Lubock | Jan 2015 | A1 |
20150133989 | Lubock | May 2015 | A1 |
20150250628 | Monstadt et al. | Sep 2015 | A1 |
20150272589 | Lorenzo | Oct 2015 | A1 |
20150313605 | Griffin | Nov 2015 | A1 |
20160022445 | Ruvalcava et al. | Jan 2016 | A1 |
20160030050 | Franano | Feb 2016 | A1 |
20160278749 | Javois et al. | Sep 2016 | A1 |
20160317277 | Carpenter et al. | Nov 2016 | A1 |
20170014114 | Radfiee et al. | Jan 2017 | A1 |
20170156734 | Griffin | Jun 2017 | A1 |
20170224350 | Shimizu et al. | Aug 2017 | A1 |
20170224355 | Bowman | Aug 2017 | A1 |
20170348014 | Wallace et al. | Dec 2017 | A1 |
20170367708 | Mayer et al. | Dec 2017 | A1 |
20170367713 | Greene, Jr. et al. | Dec 2017 | A1 |
20180049731 | Hardy et al. | Feb 2018 | A1 |
20190053810 | Griffin | Feb 2019 | A1 |
20190110796 | Jayaraman | Apr 2019 | A1 |
20190192165 | Greene, Jr. et al. | Jun 2019 | A1 |
20190192167 | Lorenzo | Jun 2019 | A1 |
20190192168 | Lorenzo | Jun 2019 | A1 |
20190223876 | Badruddin et al. | Jul 2019 | A1 |
20190223878 | Lorenzo et al. | Jul 2019 | A1 |
20190223881 | Hewitt et al. | Jul 2019 | A1 |
20190357914 | Gorochow | Nov 2019 | A1 |
20200113576 | Gorochow | Apr 2020 | A1 |
Number | Date | Country |
---|---|---|
102871700 | Apr 2015 | CN |
103006285 | Jun 2015 | CN |
102012016555 | Feb 2014 | DE |
102013006503 | Jul 2014 | DE |
0832607 | Apr 1998 | EP |
2647343 | Jul 2017 | EP |
WO199905977 | Feb 1999 | WO |
WO200200139 | Jan 2002 | WO |
WO2009055782 | Apr 2009 | WO |
WO-2009132045 | Oct 2009 | WO |
WO2012009875 | Jan 2012 | WO |
WO2015057796 | Apr 2015 | WO |
WO2015168249 | Nov 2015 | WO |
WO2017102804 | Jun 2017 | WO |
WO2017153603 | Sep 2017 | WO |
WO2017220400 | Dec 2017 | WO |
WO2019038293 | Feb 2019 | WO |
Entry |
---|
Shapiro, M., Raz, E., Becske, T., Nelson, P., “Variable Porosity of the Pipeline Embolization Device in Straight and Curved Vessels: A Guide for Optimal Deployment Strategy”, Original Research Interventional, Sep. 26, 2013, 6 pages, 10.3174/ajnr.A3742, American Society of Neuroradiology, Oak Brook, USA. |
Perez, M., Henkes, H., Bouillot, P., Brina, O., Slater, L., Pereira, V., “Intra-aneurysmal hemodynamics: evaluation of pCONus and pCANvas bifurcation aneurysm devices using DSA optical flow imaging”, Journal of NeuroInterventional Surgery, Dec. 23, 2015, 6 pages, 10.1136/neurintsurg-2015-011927, Society of NeuroInterventional, Fairfax, USA. |
Torii, R., Oshima, M., Kobayashi, T., Takagi, K., Tezduyar, T., “Fluid-structure interaction modeling of a patient-specific cerebral aneurysm: influence of structural modeling.” Computational Mechanics 43: 151-159 (2008). |
Control, etc. http://www.asianjns.org/articles/2012/7/4/images/AsianJNeurosurg_2012_7_4_159_106643_f7.jpg downloaded from internet Apr. 3, 2020. |
Cerus https://neuronewsinternational-wpengine.netdna-ssl.com/wp-content/uploads/sites/3/2016/07/Cerus-Endovascular-Contour-300x194.jpg downloaded from internet Apr. 3, 2020. |
Contour https://neuronewsinternational-wpengine.netdna-ssl.com/wp-content/uploads/sites/3/2017/06/Contour-e1497957260361-300x194.png downloaded from internet Apr. 3, 2020. |
Medtronic https://evtoday.com/images/articles/2017-02/0217-endovascular-fig1.png downloaded from internet Apr. 3, 2020. |
Bhogal, P., Udani, S., Cognard, C., Piotin, M., Brouwer, P., Sourour, N., Andersson, T., Makalanda, L., Wong, K., Fiorella, D., Arthur, A., Yeo, L., Soderman, M., Henkes, H., Pierot, L., “Endovascular flow disruption: where are we now?” Journal of Neurointerventional Surgery 11: 1024-1035 (2019). |
PCT International Search Report and Written Opinion for PCT/US2020/034450, Galaxy Therapeutics, Inc., Forms PCT/ISA/220, 210, and 237 dated Aug. 1, 2020 (11 pages). |
Number | Date | Country | |
---|---|---|---|
20200367894 A1 | Nov 2020 | US |
Number | Date | Country | |
---|---|---|---|
62852988 | May 2019 | US | |
62914442 | Oct 2019 | US | |
62975741 | Feb 2020 | US | |
62975744 | Feb 2020 | US |